Wiggans Thomas G's Form 4 filing
Pardes Biosciences, Inc. (PRDS) · filed Dec 7, 2022
- Accession no.
- 0001209191-22-060154
- Filed
- Dec 7, 2022
- Trade date
- Dec 5, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $13.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wiggans Thomas GCIK 0001208907 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 5, 2022 | Common Stock | PPurchaseAcquired | +12,500 | $1.09F1 | +$13,625 | 50,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price in Column 4 is a weighted average price. The prices actually paid ranged from $1.02 to $1.20. The reporting person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.
Referenced by the price of 1 transaction in Table I.